Videos

Clinical Factors Evaluated When Choosing Treatment in Late-Line RRMM

March 24th 2025, 8:11pm

Video

Panelists discuss how treatment selection for late-line relapsed/refractory multiple myeloma (RRMM) balances multiple factors including patient fitness, prior therapy exposure, disease aggressiveness, side effect profiles, logistical considerations (with CAR-T requiring hospitalization while bispecifics can often be administered outpatient), financial accessibility and unique toxicity considerations (such as GPRC5D-targeting therapies affecting the skin and nails versus B-cell maturation antigen [BCMA]–targeting approaches), ultimately requiring a personalized approach weighing effectiveness against practical constraints on a patient-by-patient basis.

Current Treatment Landscape for Late-Line RRMM

March 24th 2025, 8:08pm

Video

Panelists discuss how the current treatment landscape for patients with late-line relapsed/refractory multiple myeloma (RRMM) involves novel approaches such as bispecific antibodies, CAR-T cell therapies, antibody-drug conjugates and clinical trials of emerging agents, with treatment selection highly individualized based on prior therapies, resistance patterns and patient-specific factors like comorbidities, quality of life considerations and treatment goals.

Linda’s Treatment History and Challenges in Coping With Multiple Relapses

March 24th 2025, 8:05pm

Video

Panelists discuss how multiple myeloma patients often navigate through numerous treatment regimens over their disease course, frequently cycling through five to 10 different therapeutic approaches since diagnosis, with the greatest challenges being management of cumulative side effects, emotional fatigue from repeated relapses and maintaining hope while facing increasingly limited options as they progress to late-line therapy.

Challenges in Managing Late-Line RRMM

March 24th 2025, 8:03pm

Video

Panelists discuss how the term “late-line” emerged organically in clinical practice to describe patients who had exhausted multiple treatment options, with most experts recalling its growing usage over the past decade as novel therapies expanded the treatment landscape and created a need to distinguish between patients with early and more heavily pretreated relapsed/refractory multiple myeloma (R/R MM).

Dr. Sheri Prentiss on Steps for Lymphedema Screening in Breast Cancer

March 24th 2025, 8:00pm

Video

Dr. Sheri Prentiss discusses what steps patients can take to ensure they're being screened for lymphedema prior to starting their breast cancer treatment.

Emphasizing the Importance of Breast Cancer Education and Screenings

March 21st 2025, 7:00pm

Video

Registered nurse Patricia Jakel emphasizes the importance of educating patients on evolving breast cancer research and the need for routine screenings.

The Power of Knowledge and Staying Informed in Breast Cancer Care

March 20th 2025, 8:00pm

Video

Dr. Debu Tripathy highlights the importance of staying informed on breast cancer advancements and how this empowers patients to make informed decisions.

Kadcyla Continues to Show Benefits in Early HER2+ Breast Cancer

March 20th 2025, 1:00pm

Video

In HER2-positive early breast cancer, Kadcyla shows sustained improvement in both invasive disease-free survival and overall survival versus Herceptin.

How Antibody-Drug Conjugates Have Impacted HER2-Positive Breast Cancer Treatment

March 19th 2025, 8:00pm

Video

Antibody-drug conjugates have had a tremendous impact on breast cancer care and treatment, according to Dr. Charles E. Geyer.

Investigating Quality of Life and Treatment Adherence in Kidney Cancer

March 18th 2025, 7:00pm

Video

Dr. Emre Yekedüz highlighted strategies that may improve patients' quality of life and mitigate treatment-related side effects in renal cell carcinoma.